Search Results

You are looking at 51 - 60 of 135 items for :

  • "prognosis" x
Clear All
Open access

Alberto Bongiovanni, Federica Recine, Flavia Foca, Valentina Fausti, Nada Riva, Greta Fabbri, Stefano Severi, Chiara Liverani, Alessandro De Vita, Chiara Spadazzi, Giacomo Miserocchi, Laura Mercatali, Dino Amadori and Toni Ibrahim

benefits and side effects, as well as life expectancy, differ from those of their younger counterparts ( 16 ). For these reasons, little information is available on prognosis and on the risks of treatment in this subgroup, especially for those with NEN

Open access

Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole J Caixeiro, Paul DeSouza and Navin Niles

subgroups (F). Sub-analysis was performed to assess the relationship between tumoural PD-L1 expression, soluble PD-L1 levels and prognosis. Cases were divided into four groups based on positive or negative tumoural PD-L1 expression and high or low

Open access

Dirk-Jan van Beek, Rachel S van Leeuwaarde, Carolina R C Pieterman, Menno R Vriens, Gerlof D Valk and the DutchMEN Study Group

tumors (NETs) of thymic, bronchial or gastric origin, skin and subcutaneous tumors, smooth muscle tumors and breast cancer ( 5 , 6 ). Life expectancy of MEN1 patients is reduced compared to the general population ( 4 ). The prognosis of patients depends

Open access

Logan Mills, Panagiotis Drymousis, Yogesh Vashist, Christoph Burdelski, Andreas Prachalias, Parthi Srinivasan, Krishna Menon, Corina Cotoi, Saboor Khan, Judith Cave, Thomas Armstrong, Martin O Weickert, Jakob Izbicki, Joerg Schrader, Andreja Frilling, John K Ramage and Raj Srirajaskanthan

-014-3701-y ) 24740828 10.1245/s10434-014-3701-y 6 Massironi S Rossi RE Zilli A Casazza G Ciafardini C Conte D . A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival. Oncotarget 2016 7 18978 – 18983 . ( doi:10

Open access

Konstantin Yakimchuk, Chandrashekar Bangalore Revanna, Dan Huang, Jose Inzunza and Sam Okret

, 8 ). Several epidemiological studies have shown gender differences with regard to both incidence and prognosis of most lymphomas and leukemias, with men demonstrating higher incidence, worse prognosis and poorer survival ( 9 , 10 ). For example

Open access

Irvin M Modlin, Harry Aslanian, Lisa Bodei, Ignat Drozdov and Mark Kidd

Clinical Gastroenterology 2006 40 572 – 582 . ( doi:10.1097/00004836-200608000-00003 ). 3 Turner GB Johnston BT McCance DR McGinty A Watson RG Patterson CC Ardill JE . Circulating markers of prognosis and response to treatment in

Open access

Shan Wu, Jianjun Zhou, Jing Guo, Zhan Hua, Jianchen Li and Zai Wang

. Sixty-five percent of patients develop distant metastases when diagnosed and have an unfavorable prognosis ( 2 , 3 ). Currently, the medical treatments of PNETs are limited. Therefore, new drug evaluation is urgently needed. In recent years, several

Open access

T Szarvas, B Jardin-Watelet, N Bourgoin, M J Hoffmann, P Nyirády, C Oláh, T Széll, A Csizmarik, B Hadaschik and H Reis

recently been described based on gene expression data, no recommendation exists for the immunohistochemical characterization of this molecular subtype. Notably, this subtype has the most devastating prognosis with currently no specific therapeutic

Open access

Filomena Cetani, Chiara Banti, Elena Pardi, Simona Borsari, Paolo Viacava, Paolo Miccoli, Liborio Torregrossa, Fulvio Basolo, Maria Rosa Pelizzo, Massimo Rugge, Gianmaria Pennelli, Guido Gasparri, Mauro Papotti, Marco Volante, Edda Vignali, Federica Saponaro and Claudio Marcocci

diagnosis of PC, but had incomplete follow-up data (18) . Based on these findings, it might be hypothesized that patients whose tumors carry the CDC73 mutation, as compared with those who do not, might have a worse prognosis. Herein, we confirm that CDC

Open access

Sarah J Delforce, Eugenie R Lumbers, Celine Corbisier de Meaultsart, Yu Wang, Anthony Proietto, Geoffrey Otton, Jim Scurry, Nicole M Verrills, Rodney J Scott and Kirsty G Pringle

mRNA reinforces the evidence that this SNP is a potential risk factor for endometrial cancer progression. Shibata and coworkers found that higher levels of both Ang II and AGTR1 in endometrial cancer tissue predicted a poorer prognosis, whereas higher